Minted: - / 5000

4609 Atrimustine
fa2f12c6af79060a3b93e19b9dd03b53a2ea14ddc513b02bb3b0e7f72ab702f0

Properties

Background

Red
Bottle

Light green
Cap

Light green
Syringe

Blue
Bubbles
No
Drops
No
Label
-

Chemistry

Formula
C41H47Cl2NO6
Carbon
41
Polarity
Neutral

Atrimustine (developmental code name KM-2210; former tentative brand name Kregan), also known as bestrabucil or busramustine, is a cytostatic antineoplastic agent which was under development in Japan by Kureha Chemicals (now Kureha Corporation) for the treatment of breast cancer and non-Hodgkin's lymphoma as well as for the prevention of graft-versus-host disease in bone marrow transplant recipients. It is the benzoate ester of an ester conjugate of estradiol and chlorambucil, which results in targeted/site-directed cytostatic activity toward estrogen receptor-positive tissues such as breast and bone. It reached preregistration for the treatment of cancer but was ultimately discontinued. Estrogenicic side effects of atrimustine in clinical trials included vaginal bleeding and gynecomastia. The drug was first patented in 1980.

From Wikipedia, the free encyclopedia. License: CC BY-SA.